Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological, Cardiovascular, Oncological, and CNS Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HTR1B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | HTR1B Lentivirus Premade Particles Full-length GPCR for stable cell line construction. High titer (>10^8 TU/ml), Sequence Verified. Preserves native membrane conformation. |
View HTR1B Products |
| Expression Vector | HTR1B Promise-ORF Cloning Vector Codon-optimized ORF for mammalian expression systems, N-terminal flag tag. |
View HTR1B Products |
| Benchmark Control | HTR1B Reference Compound Panel & Anti-HTR1B Control Antibody Analytical standards for assay validation; recombinant positive control for flow cytometry (>95% purity). |
View HTR1B Products |
| Validator | HTR1B shRNA Lentivirus / siRNA Set For specific knockdown verification and off-target screening in cell-based functional assays. |
View HTR1B Products |
| Related Target 1 | HTR1D 5-HT1D receptor - closely related subtype for selectivity screening in migraine therapeutics. Essential counter-screening for triptan-class selectivity. |
View HTR1D Products |
| Related Target 2 | HTR1A 5-HT1A receptor - distinct functional profile for anxiety and depression comorbidity studies. |
View HTR1A Products |
| Related Target 3 | SLC6A4 (SERT) Serotonin transporter - presynaptic reuptake mechanism for combination pathway analysis. |
View SLC6A4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity (GPCR structure preservation) | Lentivirus-mediated stable expression in HEK293 cells preserves native folding and critical glycosylation patterns required for ligand binding. |
| HTR1B vs HTR1D Selectivity Screening | Human HTR1B and HTR1D ortholog lentivirus pairs available with sequence-verified specificity for discrimination assays. |
| Functional cAMP Modulation Assay | High-expression stable cell lines suitable for Gi/o-coupled cAMP inhibition assays with low background. |
| Cross-species Translation (CNS penetration models) | Human/Mouse/Rat ortholog reagents with >95% sequence homology available for translational pharmacology. |
| Lack of Validated Functional Controls | Clinical benchmark antibodies and pathway-verified siRNA tools included for robust assay validation. |
Key Genetic Variations
Notable single nucleotide polymorphisms (SNPs) in the HTR1B gene have been documented in UniProt (primary entry P28222), including rs130060, rs130061 (also known as G861C), and rs130063. These variants are of interest in population pharmacogenomics studies of HTR1B, influencing drug response variability and receptor function in migraine, depression, and addiction disorders.
Global Clinical Landscape & Future Outlook
The therapeutic targeting of HTR1B (5-HT1B receptor) is evolving rapidly beyond traditional migraine management. While first-generation triptans (e.g., sumatriptan) established the target's validity for acute migraine and cluster headache, the next wave of R&D is expanding into CNS disorders such as addiction, depression with anxiety comorbidities, and fibromyalgia. Furthermore, emerging roles in pulmonary arterial hypertension (PAH) and oncology (where the receptor is anomalously upregulated) are driving new modalities such as monoclonal antibodies and biased agonists. As the industry pivots from non-selective serotonin agonists toward subtype-selective modulators, the demand for high-fidelity HTR1B vs HTR1D discrimination assays and pathway-specific functional readouts has become critical for avoiding off-target cardiovascular and CNS side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonists | Eli Lilly, Teva, Pfizer, GSK | Migraine, Cluster Headache | Selectivity Panel (HTR1B vs HTR1D Lentivirus stable cell lines) |
| Allosteric Modulators / Biased Agonists | Sosei Heptares, Emerging Biotechs | Depression, Addiction, Anxiety | Conformational biosensor cell lines; cAMP / Beta-Arrestin assays for biased signaling |
| Combination Therapy | Lundbeck, Otsuka | Treatment-resistant Depression | Multiplex target validation (HTR1B + SLC6A4 co-expression systems) |
| Monoclonal Antibodies | Academic / Preclinical | Pulmonary Arterial Hypertension, Oncology | Epitope mapping using native membrane-bound conformation (lentivirus expressed) |
Live HTR1B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: